Israel Englander Millennium Management
Israel “Izzy” Englander is the founder of Millennium Management, one of the world’s largest multi-strategy hedge fund platforms. Millennium allocates capital across hundreds of independent teams rather than a single house view, with rigorous risk controls at the platform level. Englander’s model has been highly influential in the rise of pod-shop multi-manager structures across the industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$643M |
| 2 |
AT&T
T
|
+$311M |
| 3 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$306M |
| 4 |
Microsoft
MSFT
|
+$292M |
| 5 |
Ametek
AME
|
+$215M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$887M |
| 2 |
Apple
AAPL
|
+$694M |
| 3 |
PRAH
PRA Health Sciences, Inc.
PRAH
|
+$616M |
| 4 |
Amazon
AMZN
|
+$596M |
| 5 |
Linde
LIN
|
+$531M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 58.05% |
| 2 | Technology | 7.69% |
| 3 | Financials | 6.83% |
| 4 | Healthcare | 6.42% |
| 5 | Industrials | 4.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2601
CALL
US Bancorp
USB
$97.3B
| $6.06M | ﹤0.01% |
102,000
+25,600
| +34% | +$1.46M |
|
2602
BioCryst Pharmaceuticals
BCRX
$2.51B
| $6.06M | ﹤0.01% |
421,853
-293,287
| -41% | -$4.63M |
|
|
WPCA.U
2603
DELISTED
Warburg Pincus Capital Corporation I-A Units, each consisting of one Class A ordinary share, and one-fifth of one redeemable warrant
WPCA.U
| $6.06M | ﹤0.01% |
606,000
| – | – |
|
2604
Rush Enterprises Class A
RUSHA
$8.27B
| $6.06M | ﹤0.01% |
201,236
+73,818
| +58% | +$2.18M |
|
|
CHCT
2605
Community Healthcare Trust
CHCT
$428M
| $6.06M | ﹤0.01% |
134,063
+82,772
| +161% | +$4.01M |
|
2606
Dole
DOLE
$1.3B
| $6.05M | ﹤0.01% |
+356,944
| New | +$5.5M |
|
2607
iShares Silver Trust
SLV
$32.3B
| $6.05M | ﹤0.01% |
294,739
+179,399
| +156% | +$4.03M |
|
|
GSQD
2608
DELISTED
G Squared Ascend I Inc.
GSQD
| $6.05M | ﹤0.01% |
613,072
+64,766
| +12% | +$632K |
|
|
CRU
2609
DELISTED
Crucible Acquisition Corporation
CRU
| $6.04M | ﹤0.01% |
618,113
+302,623
| +96% | +$2.93M |
|
2610
CALL
argenx
ARGX
$64B
| $6.04M | ﹤0.01% |
+20,000
| New | +$6.34M |
|
2611
Edgewell Personal Care
EPC
$1.34B
| $6.03M | ﹤0.01% |
166,023
+141,898
| +588% | +$5.83M |
|
2612
PUT
DuPont de Nemours
DD
$18.5B
| $6.02M | ﹤0.01% |
70,585
+67,478
| +2,172% | +$6.25M |
|
2613
Mercer International
MERC
$25.9M
| $6.02M | ﹤0.01% |
519,325
-200,752
| -28% | -$2.33M |
|
2614
iShares US Transportation ETF
IYT
$2.26B
| $6M | ﹤0.01% |
98,728
+65,500
| +197% | +$4.14M |
|
|
TWCBU
2615
DELISTED
Bilander Acquisition Corp. Unit
TWCBU
| $6M | ﹤0.01% |
+600,000
| New | +$5.94M |
|
2616
EverQuote
EVER
$904M
| $6M | ﹤0.01% |
321,877
+217,312
| +208% | +$5.2M |
|
2617
Invesco S&P 500 Equal Weight ETF
RSP
$99.5B
| $5.99M | ﹤0.01% |
40,006
+6,263
| +19% | +$959K |
|
|
BTNB
2618
DELISTED
Bridgetown 2 Holdings Limited Class A Ordinary Shares
BTNB
| $5.99M | ﹤0.01% |
604,691
+159,460
| +36% | +$1.59M |
|
2619
iShares MSCI Singapore ETF
EWS
$1.23B
| $5.99M | ﹤0.01% |
262,912
+92,964
| +55% | +$2.16M |
|
2620
West Pharmaceutical
WST
$23.7B
| $5.98M | ﹤0.01% |
14,095
-7,062
| -33% | -$2.98M |
|
2621
Atmos Energy
ATO
$28.2B
| $5.97M | ﹤0.01% |
67,723
+61,387
| +969% | +$5.94M |
|
2622
Duke Energy
DUK
$93.8B
| $5.97M | ﹤0.01% |
61,206
+19,551
| +47% | +$2.02M |
|
2623
Pegasystems
PEGA
$5.95B
| $5.97M | ﹤0.01% |
93,912
+40,810
| +77% | +$2.72M |
|
|
STKL
2624
DELISTED
SunOpta
STKL
| $5.97M | ﹤0.01% |
667,966
-132,185
| -17% | -$1.34M |
|
2625
Alamos Gold
AGI
$15.4B
| $5.96M | ﹤0.01% |
827,474
+741,782
| +866% | +$5.71M |
|
Similar funds
Israel Englander's Q3 2021 Portfolio in Review
As of Q3 2021, Israel Englander held 7,698 positions worth $167B, up 2.3% from $163B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Israel Englander's Q3 2021 filing shows 1,245 new, 2,719 increased, 2,446 reduced and 981 closed positions. Its largest new stake was Sight Sciences: 1,577,092 shares worth $35.8M. The largest sale was Alexion Pharmaceuticals, an estimated $887M.
By sector, the portfolio is most concentrated in Miscellaneous at 58% of assets, up from 55% a quarter earlier, followed by Technology and Financials.
- Israel Englander's largest Q3 2021 buy was Sight Sciences: 1,577,092 shares worth $35.8M.
- Israel Englander added most to State Street SPDR S&P 500 ETF Trust in Q3 2021, an estimated $643M increase.
- Israel Englander's biggest Q3 2021 reduction was Apple, cutting an estimated $694M.
- Israel Englander fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $887M.
- Israel Englander's ten largest holdings make up 18% of its $167B portfolio in Q3 2021.
- Israel Englander opened 1,245 new positions and closed 981 in Q3 2021.
- Israel Englander's portfolio value rose 2.3% quarter-over-quarter to $167B.
Based on Millennium Management's 13F filing for Q3 2021, filed 15 Nov 2021.